NCT01756157 - Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2013

Primary Completion Date

September 13, 2013

Study Completion Date

September 13, 2013

Conditions

Hereditary Angioedema (HAE)

Interventions

BIOLOGICAL

CINRYZE with rHuPH20

Trial Locations (23)

11501

ViroPharma Investigational Site, Mineola

15241

ViroPharma Investigational Site, Pittsburgh

17033

ViroPharma Investigational Site, Hershey

33613

ViroPharma Investigational Site, Tampa

35209

ViroPharma Investigational Site, Birmingham

37909

ViroPharma Investigational Site, Knoxville

43235

ViroPharma Investigational Site, Columbus

45267

ViroPharma Investigational Site, Cincinnati

72712

ViroPharma Investigational Site, Bentonville

75231

ViroPharma Investigational Site, Dallas

80907

ViroPharma Investigational Site, Colorado Springs

85251

ViroPharma Investigational Site, Scottsdale

89106

ViroPharma Investigational Site, Las Vegas

94598

ViroPharma Investigational Site, Walnut Creek

97035

ViroPharma Investigational Site, Lake Oswego

99204

ViroPharma Investigational Site, Spokane

02114

ViroPharma Investigational Site, Boston

Unknown

ViroPharma Investigational Site, Berlin

ViroPharma Investigational Site, Essen

ViroPharma Investigational Site, Mainz

ViroPharma Investigational Site, München

ViroPharma Investigational Site, Barcelona

ViroPharma Investigational Site, Jönköping